2011
DOI: 10.1016/j.eururo.2011.07.002
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

33
445
4
11

Year Published

2012
2012
2022
2022

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 415 publications
(493 citation statements)
references
References 23 publications
33
445
4
11
Order By: Relevance
“…In another study, among 39 patients with HAM/TSP who had received pulse therapy with methylprednisolone, improvement in motor disability was observed in more than 60% of cases, but no improvements in bladder dysfunction were noted 10 . Botulinum toxin A is a neuromuscular blocking agent that can promote weakness in the detrusor sphincter muscle and control symptoms of OAB, and has been used to treat idiopathic and neurogenic detrusor overactivity in patients with multiple sclerosis, spinal cord injury, and children with OAB due to myelomeningocele 11,12 . In a double-blind clinical trial of multiple sclerosis patients, botulinum toxin A was not only more effective than placebo, but 60% of the patients who had received botulinum toxin A had no urinary loss for up to 12 weeks 11 .…”
mentioning
confidence: 99%
“…In another study, among 39 patients with HAM/TSP who had received pulse therapy with methylprednisolone, improvement in motor disability was observed in more than 60% of cases, but no improvements in bladder dysfunction were noted 10 . Botulinum toxin A is a neuromuscular blocking agent that can promote weakness in the detrusor sphincter muscle and control symptoms of OAB, and has been used to treat idiopathic and neurogenic detrusor overactivity in patients with multiple sclerosis, spinal cord injury, and children with OAB due to myelomeningocele 11,12 . In a double-blind clinical trial of multiple sclerosis patients, botulinum toxin A was not only more effective than placebo, but 60% of the patients who had received botulinum toxin A had no urinary loss for up to 12 weeks 11 .…”
mentioning
confidence: 99%
“…[9][10][11] We were able to make a number of associations regarding the presence of coexisting symptoms. For women with II alone, when a cause of incontinence was demonstrated, USUI was found in 81% of women.…”
Section: Discussionmentioning
confidence: 99%
“…Botulinum toxin A has also been examined among patients with neurologic problems (mixed populations of MS and spinal cord injury). [8][9][10] In these studies, more than half the patients treated experienced significant improvement in symptoms. Indeed, as many as 76% of patients in one trial achieved complete continence.…”
Section: A Urological Challenge: Voiding Dysfunction In Multiple Sclementioning
confidence: 98%